Connect to other sites within the UBM Medica Network
ASCO has endorsed a clinical practice guideline from several associations on when to offer molecular testing for EGFR and ALK mutations in lung cancer patients.
Anti-PD-1 Drug Improves Survival in NSCLC, Trial Halted
A study of nivolumab compared with docetaxel in patients with squamous cell NSCLC was stopped early after an analysis showed superiority of the study drug.
A Lung Cancer Screening “Shared Decision-Making” Session
This one-act play features a patient, former smoker, navigating the CMS rules for lung cancer CT screening in a shared decision-making session with his doctor.
ASCO/AACR Experts Advocate for E-Cigarette Regulations
Experts from ASCO and AACR have penned a statement for policymakers on the potential negative effects of e-cigarettes and other nicotine-deliveries electronics.
Linifanib With Chemotherapy Improves PFS in NSCLC
Adding linifanib to a carboplatin/paclitaxel regimen improved progression-free survival over placebo in advanced non-squamous NSCLC patients.
Two Regimens Yield Similar Survival in Advanced NSCLC
An analysis showed that etoposide-cisplatin or carboplatin-paclitaxel with RT yielded similar survival in patients with stage III non-small-cell lung cancer.
Ramucirumab-Docetaxel Approved for Advanced NSCLC
The FDA has approved the combination of ramucirumab and docetaxel for the treatment of patients with metastatic non-small-cell lung cancer.
Amrubicin Edges Topotecan for Survival in Refractory SCLC
In a new trial, amrubicin showed a slight improvement for patients with refractory small-cell lung cancer in the second-line setting.
Oncogenic Drivers in Lung Cancer
From the 2014 ASCO Annual Meeting, this internationally renowned lung cancer expert discusses oncogenic driver mutations in lung cancer.
ASCO: Current and Upcoming Lung Cancer Research
Dr. Ramaswamy Govindan, Washington U at St. Louis, discusses patient screening, new research in targeted therapies, as well as the continued role of traditional chemotherapy in lung cancer.
ASCO: Controversies in the Treatment of Mesothelioma of the Pleura
In this exclusive video, Dr. Harvey Pass discusses surgery in mesothelioma of the pleura and other areas of disagreement.
ASCO: Chemotherapy Key Part of Curative Lung Cancer Therapies
As part of our coverage of the 2014 ASCO Annual Meeting, we discuss chemotherapy's curative role in treating lung cancer.
Combination Therapies for Lung Cancer
As part of our coverage of the AACR Annual Meeting, we discuss combination therapies and new research in the treatment of lung cancer.
Oncogenes Driving Squamous Cell Lung Carcinoma
In this interview we discuss the oncogenes driving the development of squamous cell carcinoma of the lung, a type of non-small-cell lung cancer.
Lung Cancer Prevention and Screening
In this interview we discuss lung cancer prevention, the recent low-dose CT screening recommendations from the USPSTF, hurdles in preventing the disease, and more.
By clicking Accept, you agree to become a member of the UBM Medica Community.